The latest market report published by Credence Research, Inc. ?Irritable Bowel Syndrome with Constipation Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2018 -2026? the irritable bowel syndrome with constipation drugs market was valued at US$ 1.30 Bn in 2017, and is expected to reach US$ 2.23 Bn by 2026, expanding at a CAGR of 6.2% from 2018 to 2026. 

Browse the full report Irritable Bowel Syndrome with Constipation Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2018 -2026 report at http://www.credenceresearch.com/report/irritable-bowel-syndrome-with-constipation-drugs-market

Market Insights

The global IBS-C drugs market is expected to progress at a CAGR of 6.2% during the forecast period from 2018 to 2026. North America is expected to be the largest regional market for IBS-C drugs followed by Europe and Asia Pacific. Gradual growth in physician and patient awareness corresponding to the perpetual growth in disease prevalence are the major growth contributors to the global IBS-C drugs market. 

The global IBS-C drugs market is expected to witness significant growth over the forecast period due to widespread adoption of IBS-C drugs. The recent FDA approvals and currently successful clinical trials of IBS drugs will further surge the market opportunities for IBS-C drugs during the forecast period. Pipeline products namely tenapanor, SYN-010 and relenopride are being developed for the treatment of IBS-C. The approval of these drugs would contribute to the further growth of the IBS-C drugs market. 

Growing geriatric population and rise in healthcare expenditure are further creating huge opportunities in the IBS-C drugs market. IBS-C is much prevalent in developed world, where dietary habits and work conditions contribute to higher risk of lifestyle-related gastrointestinal diseases. Majority of IBS-C drugs are widely accepted and the rise in FDA approvals to newer drugs are adding up to create further market opportunities. As a result, several market players are increasingly focusing on research and development activities to come with better and novel pharmaceutical solutions for treating IBS-C. 

North America predominates the IBS-C market owing to the rising prevalence of IBS-C patients, constant R&D activities, greater geriatric population, rise in adoption of unhealthy lifestyle and presence of manufacturers across this region. Plecanatide (Trulance) by Synergy Pharmaceuticals has been sent for NDA filling to the FDA (2017). Upon approval, it would contribute to the remunerative growth of IBS-C drugs market.

Market Competition Assessment:

Irritable bowel syndrome with constipation drugs market comprises a narrow competitive pool, thus creating opportunities for new emerging market players. Synergy Pharmaceuticals, Inc. has recently filed an NDA for its product Plecanatide (Trulance) for the treatment of IBS-C. Potential players contributing to this market are Abbott Laboratories, Inc., Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Fresenius Kabi AG, Ironwood Pharmaceuticals, Inc., Sanofi S.A., SK Biopharmaceuticals Co., Ltd., Sucampo AG and Synthetic Biologics, Inc.

Key Market Movements:

• Constant rise in the adoption of unhealthy lifestyle has led to the rise in prevalence of IBS-C across the globe thus facilitating the growth of IBS-C drugs market
• Suitable diagnostic techniques for IBS-C still remains a major unmet need, which could restraint the growth of the market
• Increased pipeline products for IBS-C would fuel the growth of the market in the forecast period

Browse the full report Irritable Bowel Syndrome with Constipation Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2018 -2026 report at http://www.credenceresearch.com/report/irritable-bowel-syndrome-with-constipation-drugs-market

 Blog: http://www.mobilecomputingtoday.co.uk/6517/laxatives-market-expected-reach-us8-71bn-2025-support-growth-market-6-9-cagr-credence-research/

Irritable bowel syndrome (IBS) is a group of symptoms?including abdominal pain and changes in the pattern of bowel movements without any evidence of underlying damage. These symptoms occur over a long time, often years.  It has been classified into four main types depending on whether diarrhea is common, constipation is common, both are common, or neither occurs very often (IBS-D, IBS-C, IBS-M, or IBS-U respectively). IBS negatively affects quality of life and may result in missed school or work. Disorders such as anxiety, major depression, and chronic fatigue syndrome are common among people with IBS.

Constipation refers to bowel movements that are infrequent or hard to pass. The stool is often hard and dry. Other symptoms may include abdominal pain, bloating, and feeling as if one has not completely passed the bowel movement. Complications from constipation may include hemorrhoids, anal fissure or fecal impaction. The normal frequency of bowel movements in adults is between three per day and three per week. Babies often have three to four bowel movements per day while young children typically have two to three per day. Source: Wikipedia

 Latest Reports: https://globenewswire.com/news-release/2018/03/13/1421270/0/en/Global-Algae-Products-Market-is-Expected-to-Reach-US-44-7-Billion-By-2023-Credence-Research.html

About:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared for this task.

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph: 1-800-361-8290
Web: http://www.credenceresearch.com